![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ALKBH2 |
Gene summary for ALKBH2 |
![]() |
Gene information | Species | Human | Gene symbol | ALKBH2 | Gene ID | 121642 |
Gene name | alkB homolog 2, alpha-ketoglutarate dependent dioxygenase | |
Gene Alias | ABH2 | |
Cytomap | 12q24.11 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6NS38 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
121642 | ALKBH2 | C08 | Human | Oral cavity | OSCC | 3.07e-34 | 6.26e-01 | 0.1919 |
121642 | ALKBH2 | LN22 | Human | Oral cavity | OSCC | 5.73e-06 | 9.15e-01 | 0.1733 |
121642 | ALKBH2 | LN46 | Human | Oral cavity | OSCC | 1.15e-12 | 7.02e-01 | 0.1666 |
121642 | ALKBH2 | LP15 | Human | Oral cavity | LP | 3.64e-05 | 7.41e-01 | 0.2174 |
121642 | ALKBH2 | SYSMH2 | Human | Oral cavity | OSCC | 2.76e-08 | 3.57e-01 | 0.2326 |
121642 | ALKBH2 | SYSMH3 | Human | Oral cavity | OSCC | 7.02e-25 | 7.11e-01 | 0.2442 |
121642 | ALKBH2 | SYSMH4 | Human | Oral cavity | OSCC | 6.37e-03 | 9.02e-02 | 0.1226 |
121642 | ALKBH2 | P4_S8_cSCC | Human | Skin | cSCC | 1.47e-02 | 4.17e-02 | -0.3095 |
121642 | ALKBH2 | P1_cSCC | Human | Skin | cSCC | 3.22e-11 | 5.34e-01 | 0.0292 |
121642 | ALKBH2 | P2_cSCC | Human | Skin | cSCC | 7.78e-12 | 4.02e-01 | -0.024 |
121642 | ALKBH2 | P4_cSCC | Human | Skin | cSCC | 8.14e-11 | 3.86e-01 | -0.00290000000000005 |
121642 | ALKBH2 | P10_cSCC | Human | Skin | cSCC | 8.56e-07 | 3.27e-01 | 0.1017 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006304 | Esophagus | ESCC | DNA modification | 68/8552 | 120/18723 | 9.95e-03 | 3.42e-02 | 68 |
GO:0070989 | Liver | Cirrhotic | oxidative demethylation | 10/4634 | 19/18723 | 8.23e-03 | 3.83e-02 | 10 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALKBH2 | SNV | Missense_Mutation | c.62N>G | p.Glu21Gly | p.E21G | Q6NS38 | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | |
ALKBH2 | SNV | Missense_Mutation | c.578G>C | p.Arg193Thr | p.R193T | Q6NS38 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ALKBH2 | SNV | Missense_Mutation | c.725N>T | p.Lys242Met | p.K242M | Q6NS38 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
ALKBH2 | SNV | Missense_Mutation | c.355G>A | p.Gly119Arg | p.G119R | Q6NS38 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ALKBH2 | SNV | Missense_Mutation | novel | c.718G>A | p.Val240Met | p.V240M | Q6NS38 | protein_coding | deleterious(0.04) | benign(0.192) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ALKBH2 | SNV | Missense_Mutation | c.26N>T | p.Ala9Val | p.A9V | Q6NS38 | protein_coding | tolerated_low_confidence(0.14) | benign(0.003) | TCGA-B5-A11O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ALKBH2 | SNV | Missense_Mutation | rs141848154 | c.695C>T | p.Thr232Met | p.T232M | Q6NS38 | protein_coding | tolerated(0.06) | possibly_damaging(0.524) | TCGA-DI-A1C3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALKBH2 | SNV | Missense_Mutation | novel | c.544A>G | p.Ser182Gly | p.S182G | Q6NS38 | protein_coding | tolerated(0.1) | benign(0.03) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALKBH2 | SNV | Missense_Mutation | novel | c.479G>T | p.Arg160Met | p.R160M | Q6NS38 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALKBH2 | SNV | Missense_Mutation | novel | c.782N>C | p.Lys261Thr | p.K261T | Q6NS38 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.784) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |